




# PHARMACEUTICAL 2017

NeuroBo Pharmaceuticals Inc.  
Rank 103 of 292





# PHARMACEUTICAL 2017

NeuroBo Pharmaceuticals Inc.  
Rank 103 of 292

The relative strengths and weaknesses of NeuroBo Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NeuroBo Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 128% points. The greatest weakness of NeuroBo Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 145%, being 142% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	24,746
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,121
Liabilities, Non-Current	1.0
Other Assets	8.0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	110
Other Revenues	0
Property and Equipment	0
Research and Development	8,740
Selling, General and Administrative Expense	5,956

Output Variable	Value in 1000 USD
Assets	24,754
Liabilities	4,122
Expenses	14,696
Revenues	0
Stockholders Equity	20,632
Net Income	-14,586
Comprehensive Net Income	-14,586
Economic Capital Ratio	145%